Abstract
We use data from seven low and middle income countries with diverse drug procurement systems to assess the eect of centralized procurement on drug prices, and provide a theoretical mechanism that explains this eect. Our empirical analysis is based on exhaustive data on drug sales quantities and expenditures over three years for forty important molecules. We nd that centralized procurement of drugs by the public sector leads to lower prices but that the induced price reduction is smaller when the supply side is more concentrated.
Keywords
Drugs, Procurement, Low and Middle Income Countries.;
Replaces
Pierre Dubois, Yassine Lefouili, and Stéphane Straub, “Pooled Procurement of Drugs in Low and Middle Income Countries”, TSE Working Paper, n. 19-999, March 2019, revised December 2020.
Reference
Pierre Dubois, Yassine Lefouili, and Stéphane Straub, “Pooled Procurement of Drugs in Low and Middle Income Countries”, European Economic Review, vol. 132, n. 103655, February 2021.
See also
Published in
European Economic Review, vol. 132, n. 103655, February 2021